New and emerging treatment approaches to lupus

References

• TragerJWardMMMortality and causes of death in systemic lupus erythematosusCurr Opin Rheumatol20011334535111604587
   PubMed Web of Science ®Google Scholar
• Abu-ShakraMUrowitzMBGladmanDDGoughJMortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortalityJ Rheumatol199522126512707562756
   PubMed Web of Science ®Google Scholar
• JacobsenSPetersenJUllmanSMortality and causes of death of 513 Danish patients with systemic lupus erythematosusScand J Rheumatol199928758010229135
   PubMed Web of Science ®Google Scholar
• KorbetSMLewisEJSchwartzMMfor Lupus Nephritis Collaborative Study GroupFactors predictive of outcome in severe lupus nephritisAm J Kidney Dis20003590491410793026
   PubMed Web of Science ®Google Scholar
• MoroniGQuagliniAMaccarioMBanfiGPonticelliC“Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritisKidney Int199650204720538943489
   PubMed Web of Science ®Google Scholar
• ChanTMLiFKTangCSfor Hong Kong-Guangzhou Nephrology Study GroupEfficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritisN Engl J Med20003431156116211036121
   PubMed Web of Science ®Google Scholar
• GinzlerEMDooleyMAAranowCMycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisN Engl J Med20053532219222816306519
   PubMed Web of Science ®Google Scholar
• AppelGBContrerasGDooleyMAMycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritisJ Am Soc Nephrol2009201103111219369404
   PubMed Web of Science ®Google Scholar
• HaubitzMAcute and long-term toxicity of cyclophosphamideTransplantationsmedizin2007192631
   Google Scholar
• EdwardsJCSzczepanskiLSzechinskiJEfficacy of B-cell-targeted therapy with rutuximab in patients with rheumatoid arthritisN Engl J Med20043502572258115201414
   PubMed Web of Science ®Google Scholar
• BhatPRadhakrishnanJB lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapiesKidney Int20087326126818004299
   PubMed Web of Science ®Google Scholar
• MerrillJTNeuweltCMWallaceDJEfficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosusArthritis Rheum20106222223320039413
   PubMed Web of Science ®Google Scholar
• FurieRLooneyRJRovinBEfficacy and safety of rituximab in subjects with active proliferative lupus nephritis: results from the randomized, double-blind Phase III LUNAR StudyArthritis Rheum200960Suppl 101149
   Google Scholar
• LuTYTNgKPCombrodgeGA retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first fifty patientsArthritis Rheum20096148248719333973
   PubMed Web of Science ®Google Scholar
• LapsiwalaAParhizgarAGhahramaniNA systematic review and meta-analysis of rituximab in refractory lupus nephritisAm Soc of Nephrol2009 Abstract F-PO 1289.
   Google Scholar
• RobakERobakTMonoclonal antibodies in the treatment of systemic lupus erythematosusCurr Drug Target2009102637
   PubMed Web of Science ®Google Scholar
• DörnerTKaufmannJWegenerWATeohNGoldenbergDMBurmesterGRInitial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusArthritis Res Ther20068111
   Web of Science ®Google Scholar
• WallaceDHobbsKHoussiauFRandomized controlled trials of epratuzumab (anti-CD22 mab targeting B-cells) reveal clinically meaningful reductions in corticosteroid use with favourable safety profile in moderate and severe flaring SLE patientsAnn Rheum Dis200867Suppl 2S212
   Google Scholar
• Alarcon-SegoviaDTumlinJAFurieRALJP 394 for the prevention of renal flare in patients with systemic lups erythematosus: results from a randomized, double-blind, placebo-controlled studyArthritis Rheum20034844245412571854
   PubMed Web of Science ®Google Scholar
• HorowitzDMFurieRAAbetimus sodium: a medication for the prevention of lupus nephritis flaresExpert Opin Pharmacother2009101501150719505217
   PubMed Web of Science ®Google Scholar
• JacobiAMHuangWWangTEffect of long-term belimumab treatment on B-cells in systemic lupus erythematosusArthritis Rheum20106220121020039404
   PubMed Web of Science ®Google Scholar
• WallaceDJStohlWFurieRAA phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumbab in patients with active systemic lupus erythematosusArthritis Rheum2009611168117819714604
   PubMed Web of Science ®Google Scholar
• NavarraSGuzmanRGallacherABelimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the Phase 3 BLISS-52 studyAmerican College of Rheumatology2009 Abstract LB1.
   Google Scholar
• ZhouYBYeRGLiYJXieCMWuYHEffect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB miceAutoimmunity20084139540418568645
   PubMed Web of Science ®Google Scholar
• SchifferLSinhaJWangXShort term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex depositionJ Immunol200317148949712817034
   PubMed Web of Science ®Google Scholar
• MerrillJTBurgos-VargasRWesthovensRActivity of abatacept in SLE: results of a 12-month phase II exploratory studyAnn Rheum Dis200968Suppl 3S70
   Google Scholar
• KalunianKCDavisJCJrMerrillJTTreatment of systemic lupus erythematosus by inhibition of T-cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trialArthritis Rheum2002463251325812483729
   PubMed Web of Science ®Google Scholar
• BoumpasDTFurieRManziSA short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritisArthritis Rheum20034871972712632425
   PubMed Web of Science ®Google Scholar
• SuntharalingamGPerryMRWardSCytokine storm in a phase I trial of the anti-CD28 monoclonal antibody TGN1312N Engl J Med20063551018102816908486
   PubMed Web of Science ®Google Scholar
• MoroniGDoriaAPonticelliCCyclosporine A in lupus nephritis: assessing the evidenceNephrol Dial Transplant200924152018852191
   PubMed Web of Science ®Google Scholar
• FuLWYangLYChenWPClinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuriaBr J Rheumatol1998372172219569080
   PubMedGoogle Scholar
• MoroniGDoriaAMoscaMA randomized pilot trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis over four yearsClin J Am Soc Nephrol2006192593217699309
   PubMed Web of Science ®Google Scholar
• AustinHAIlleiGGBraunMFBalowJERandomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathyJ Am Soc Nephrol20092090191119297556
   PubMed Web of Science ®Google Scholar
• MokCCTongKHToCHTacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot studyKidney Int20056881381716014060
   PubMed Web of Science ®Google Scholar
• QuLWangSChenJClinical analysis of tacrolimus therapy versus intermittent cyclophosphamide pulse treatment in lupus nephritisAmerican Society of Nephrology2009 PO237:Abstract.
   Google Scholar
• LiXRenHZhangWInduction therapies for proliferative lupus nephritis: mycophenolate mofetil, tacrolimus and intravenous cyclophosphamideAmerican Society of Nephrology2009 PO1221:Abstract.
   Google Scholar
• FernandezDBonillaEMirzaNNilandBPerlARapamycin reduces disease activity and normalizes T-cell activation-induced calcium fluxing in patients with systemic lupus erythematosusArthritis Rheum2006542983298816947529
   PubMed Web of Science ®Google Scholar
• MedinaFFuentesJCarranzaISirolimus: a potential treatment for diffuse proliferative lupus nephritisAnn Rheum Dis200665351
   Web of Science ®Google Scholar
• MerkelSMogilevskajaNMengelMHallerHSchwarzASide effects of sirolimusTransplant Proc20063871471516647452
   PubMed Web of Science ®Google Scholar
• KiberdBAStadnykAWEstablished murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule?Immunopharmacology1995301311378530254
   PubMed Web of Science ®Google Scholar
• AringerMSmolenJSTNF inhibition in SLE: where do we stand?Lupus2009185819074162
   PubMed Web of Science ®Google Scholar
• NeradovaAStamFvan den BergJGBaxWAEtanercept-associated SLE with lupus nephritisLupus20091866766819433471
   PubMed Web of Science ®Google Scholar
• LuongJMTanBTBuchananRRSchachnaLTumour necrosis factor inhibitor-related lupus: safety of switching agentsClin Rheumatol20102955155320119843
   PubMed Web of Science ®Google Scholar
• SaadAAAshcroftDMWatsonKDSymmonsDPMNoycePRHyrichKLEfficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterRheumatology20104969770520056769
   PubMed Web of Science ®Google Scholar
• IshidaHMuchamuelTSakaguchiSContinuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/WF1 miceJ Exp Med19941793053108270873
   PubMed Web of Science ®Google Scholar
• LlorenteLRichaud-PatinYGarcia-PadillaCClinical and biological effects of anti-IL-10 monoclonal antibody administration in systemic lupus erythematosusArthritis Rheum 200431790180010943869
   PubMed Web of Science ®Google Scholar
• MiharaMTakagiNTakedaYOhsugiYIL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 miceClin Exp Immunol19981123974029649207
   PubMed Web of Science ®Google Scholar
• IlleiGGShirotaYYarboroCHTocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation studyArthritis Rheum20106254255220112381
   PubMed Web of Science ®Google Scholar
• RönnblamlElorantaMLAlmGVThe type I interferon system in systemic lupus erythematosusArthritis Rheum20065440842016447217
   PubMed Web of Science ®Google Scholar
• BaechlerECBatliwallaFMKarypisGInterferon-inducible gene expression signature in peripheral blood cells of patients with severe lupusProc Natl Acad Sci U S A20031002610261512604793
   PubMed Web of Science ®Google Scholar
• YaoYRichmanLHiggsBWNeutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosusArthritis Rheum2009601785179619479852
   PubMed Web of Science ®Google Scholar
• WallaceDJPetriMAOlsenMMEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosusArthritis Rheum200756526527
   Google Scholar
• SthoegerZMSharabiAMoladYTreatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide). Immunomodulation of gene expressionHum Immunol2009337782
   Google Scholar
• FurieRMatisLRolinsSA single dose, placebo-controlled, double blind, phase I study of the humanized anti-C5 antibody hbG1 in patients with systemic lupus erythematosusAmerican College of Rheumatology2004 Abstract.
   Google Scholar
• BurtRKTraynorAStatkuteLNonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosusJAMA200629552753516449618
   PubMed Web of Science ®Google Scholar
• FargeDLabopinMTyndallAAutologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years of experience from the european group for blood and marrow transplantation working party on autoimmune diseasesHaematologica20109528429219773265
   PubMed Web of Science ®Google Scholar
• SunLAkiyamaKZhangHMesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humansStem Cells2009271421143219489103
   PubMed Web of Science ®Google Scholar
• AndersHJPseudoviral immunity – a novel concept for lupusTrends Mol Med20091555356119896418
   PubMed Web of Science ®Google Scholar
• PatolePSZecherDPawarRdGröneHjkSchlöndorffDAndersHJG-rich DNA suppresses systemic lupusJ Am Soc Nephrol2005163273328016176997
   PubMed Web of Science ®Google Scholar
• HasegawaHChemokine blockade for lupus model miceFront Biosci2008132900290817981762
   PubMed Web of Science ®Google Scholar
• KümpersPDavidSHaubitzMThe Tie2 receptor antagonist angiopoietin2 facilitates vascular inflammation in systemic lupus ery-thematosusAnn Rheum Dis2009681638164318930996
   PubMed Web of Science ®Google Scholar
• HaubitzMIs individualized therapy the future of lupus treatment?Future Rheumatol20083143151
   Google Scholar